All Posts Tagged With: "BMY"

(ONCY) Oncolytics Biotech Sees Promising Data on Reolysin

Recently, Oncolytics Biotech Inc. (ONCY) reported positive preliminary results from the US phase II trial (REO 020) evaluating the use of oncology candidate, Reolysin in combination with Bristol-Myers Squibb‘s...

1Sep2013 | | Comments Off | Continued

(GILD) Gilead’s Sofosbuvir under European Review

Gilead Sciences Inc. (GILD) recently announced that its Marketing Authorisation Application (MAA) for HCV candidate sofosbuvir (formerly GS-7977), submitted to the European Medicines Agency (EMA) on Apr 17, 2013, has been validated...

4Aug2013 | | Comments Off | Continued

(BMY) Bristol-Myers Squibb Company Earns Good News From FDA

Bristol-Myers Squibb Company (BMY) recently received positive news from the US Food and Drug Administration (FDA) when the US regulatory authority approved the pharma major’s HIV drug Sustiva for treating children between three months...

18May2013 | | Comments Off | Continued

(MRK) Merck & Company Joins Forces With Bristol-Myers Squibb on Hepatitis C Virus Candidates

Merck & Co. Inc. (MRK) recently joined forces with Bristol-Myers Squibb (BMY) to conduct a phase II study with their hepatitis C virus (HCV) candidates. The study will evaluate the safety and efficacy of a once-daily oral combination...

14May2013 | | Comments Off | Continued

(LLY) Eli Lilly and Company Sees Positive Data on Diabetes Candidate

Eli Lilly and Company (LLY) recently announced top-line data on its type II diabetes candidate, dulaglutide. The company said that dulaglutide met its primary endpoint in two phase III studies (AWARD-2 and AWARD-4) which are a part...

3May2013 | | Comments Off | Continued

(MDCO) The Medicines Company Earnings Increase

The Medicines Company (MDCO) reported first quarter earnings of 24 cents per share, compared with the year-ago earnings of 14 cents per share. Including one-time items, the company reported a loss of 21 cents per share compared...

29Apr2013 | | Comments Off | Continued

(GILD) Gilead Sciences Seeks FDA Approval

Gilead Sciences (GILD) recently submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval to market its hepatitis C Virus (HCV) candidate sofosbuvir (formerly GS-7977). Gilead is looking...

18Apr2013 | | Comments Off | Continued

(MRK) Pharma & Biotech Stock Outlook – Apr 2013 – Zacks Analyst Interviews

The pharmaceutical industry has been showing signs of recovery from one of the biggest patent cliffs in recent times. The last few quarters saw major blockbusters like Merck’s (MRK) Singulair, Pfizer’s (PFE)...

7Apr2013 | | Comments Off | Continued

(JNJ) MedTech Industry Stock Outlook – January 2013 – Zacks Analyst Interviews

We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide medical devices market. The US still holds the leading position with almost one-third of the market share. However, emerging economies like Brazil, Russia, India and China –...

31Jan2013 | | Comments Off | Continued

(AZN) Management Expands at AstraZeneca

AstraZeneca (AZN) recently announced that the company has created seven positions in the senior executive team. At the same time, two senior roles were discontinued. We note that three of the seven newly created positions are...

22Jan2013 | | Comments Off | Continued

(AAPL) Fourth Quarter 2012 Earnings Season Gets Into High Gear – Earnings Preview

The fourth quarter reporting season gets into high gear this week, with 253 companies coming out with quarterly results, including 83 S&P 500 companies. The earnings season thus far has been relatively uneventful, but we will have a better idea by the end of this week; by then we will have seen...

20Jan2013 | | Comments Off | Continued

(ARQL) ArQule Shares Fall on Oncology Drug Candidate Setback

ArQule Inc. (ARQL) and partner Daiichi Sankyo recently announced disappointing phase II results on oncology candidate, tivantinib (ARQ 197). The study evaluated ArQule’s lead pipeline candidate, tivantinib, in combination with...

16Jan2013 | | Comments Off | Continued

(MDCO) The Medicines Company Sees Positive Results on Cangrelor

The Medicines Company (MDCO) recently received good news with the company announcing positive results on its phase III candidate, cangrelor. Cangrelor is being developed for the prevention of platelet activation and aggregation that...

15Jan2013 | | Comments Off | Continued

(BMY) Takeda Pharmaceutical Company Limited Terminates Amylin Agreement

Takeda Pharmaceutical Company Limited (TKPYY) recently announced that it has mutually terminated its worldwide agreement with Amylin Pharmaceuticals, Inc., a wholly-owned subsidiary of Bristol-Myers Squibb (BMY). Takeda...

1Jan2013 | | Comments Off | Continued

(MDCO) The Medicines Company Strikes Two Deals

The Medicines Company (MDCO) recently signed two agreements in a bid to boost its top line. While one agreement relates to the in-licensing of a product, the other is an acquisition deal. Both deals will see the company making upfront...

23Dec2012 | | Comments Off | Continued

(MRK) Pharmaceuticals and Biotech Stock Outlook – December 2012 – Industry Outlook

The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The last few quarters saw major blockbusters like Merck’s (MRK) Singulair, Pfizer’s...

7Dec2012 | | Comments Off | Continued

(ARIA) ARIAD Pharmaceuticals Sees Data Published on Drug Candidate

ARIAD Pharmaceuticals (ARIA) recently announced the publishing of results from a phase I dose-escalation study of ponatinib in the New England Journal of Medicine. Ponatinib, a tyrosine kinase...

4Dec2012 | | Comments Off | Continued

(GILD) Gilead Sciences Reports Positive HCV Data

Gilead Sciences (GILD) recently presented encouraging top-line data from a phase III study (Positron) which evaluated its candidate sofosbuvir (formerly GS-7977) combined with ribavirin in patients suffering...

4Dec2012 | | Comments Off | Continued

(IMF) U.S. Fiscal Cliff and Other Concerns

On Thursday, the major U.S. stock indices fell for the second day in a row with the S&P 500 moving below its 200-day moving average. However, even pessimistic analysts do not believe that the market fall will resemble a falling knife from here on, as it encounters pretty strong support at these...

3Dec2012 | | Comments Off | Continued

(AZN) AstraZeneca’s Forxiga Gets EU Approval

Recently, AstraZeneca (AZN) and Bristol-Myers Squibb (BMY) announced that their type II diabetes candidate, Forxiga (dapagliflozin) has received European approval....

15Nov2012 | | Comments Off | Continued

(SNY) Generics Hit Sanofi Again

Sanofi (SNY) reported third quarter 2012 business earnings of $1.05 per American Depositary Share (ADS), much lower than the year-ago earnings of $1.27 per ADS. The Zacks Consensus Estimate stood at 99 cents per ADS. The company’s...

6Nov2012 | | Comments Off | Continued

(WMT) Stock Market News for October 16, 2012 – Market News

Strong September retail sales data coupled with better-than-expected quarterly results by Citigroup drove the benchmarks into the positive territory yesterday. The positive tone helped benchmarks to rebound from its previous week’s losses and guided Dow to register its biggest gain in one month....

16Oct2012 | | Comments Off | Continued

(ARIA) ARIAD Pharmaceuticals Seeks Ponatinib Approval

ARIAD Pharmaceuticals, Inc. (ARIA) recently completed the rolling submission of the New Drug Application (NDA) for its oncology candidate, ponatinib, to the US Food and Drug Administration (FDA). The rolling submission was completed...

9Oct2012 | | Comments Off | Continued

(LIFE) Life Technologies Partners with Bristol-Myers

In an attempt to develop its diagnostics business, Life Technologies (LIFE) entered into a Master Development Agreement with Bristol-Myers Squibb (BMY) for companion...

9Oct2012 | | Comments Off | Continued

(ALKS) Back to Neutral on Alkermes

We are moving back to a Neutral recommendation on Alkermes plc (ALKS) as we believe the stock is fairly valued at current levels. Our target price is $20.00. The stock carries a Zacks #3 Rank (Hold rating) in the short run. The...

9Oct2012 | | Comments Off | Continued

(SNN) MedTech Industry Stock Outlook – October 2012 – Zacks Analyst Interviews

The global medical devices industry is fairly large, intensely competitive and highly innovative. A regulated industry, MedTech is spread across different segments including cardiology, cardiovascular, neuro, orthopedic and aesthetic devices. The US medical devices industry relies largely on an aging...

4Oct2012 | | Comments Off | Continued

(ARIA) ARIAD Pharmaceuticals Seeks European Medicines Agency Nod for Ponatinib

ARIAD Pharmaceuticals, Inc. (ARIA) recently submitted a Marketing Authorization Application (MAA) for its BCR-ABL inhibitor, ponatinib, to the European Medicines Agency (EMA). ARIAD is looking to get the candidate approved in the...

3Sep2012 | | Comments Off | Continued

(IDIX) Idenix Pharmaceuticals Sees Pipeline Setback

Idenix Pharmaceuticals, Inc. (IDIX) recently suffered a huge setback when it received a verbal notice from the US Food and Drug Administration (FDA) placing a partial clinical hold on its hepatitis C candidate, IDX184. IDX184, a nucleotide...

27Aug2012 | | Comments Off | Continued

(SCR) Simcere Pharmaceutical Group Misses Second Quarter Estimates

Simcere Pharmaceutical Group’s (SCR) second quarter 2012 earnings of 8 cents per American Depositary Share (ADS), a couple of cents below the Zacks Consensus Estimate and well below the year-ago earnings of 21 cents. Lower-than-expected...

22Aug2012 | | Comments Off | Continued

(PRX) Par Pharmaceuticals Companies to be Aquired by TPG

Yet another acquisition agreement was recently announced in the pharma sector. US based specialty pharmaceutical company Par Pharmaceuticals Companies Inc. (PRX) entered into an agreement with an affiliate of leading global private...

21Aug2012 | | Comments Off | Continued